Boehringer, Lilly resubmit empagliflozin NDA

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) said Boehringer resubmitted an NDA to FDA for empagliflozin to treat Type II diabetes. The resubmission follows an FDA i...